Kymera Therapeutics (NASDAQ:KYMR) CFO Bruce N. Jacobs Sells 79,220 Shares

Key Points

• Bruce Jacobs, CFO of Kymera Therapeutics, sold 79,220 shares for approximately $3.96 million, resulting in a 25.84% decrease in his ownership.
• Kymera reported a loss of $0.95 per share for the last quarter, missing analysts' estimates, and experienced a 55.1% decline in revenue year-over-year.
• Research analysts have a consensus rating of “Buy” for Kymera Therapeutics, with an average price target of $59.42, indicating positive sentiment despite recent challenges.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) CFO Bruce N. Jacobs sold 79,220 shares of the company's stock in a transaction dated Wednesday, September 17th. The stock was sold at an average price of $50.00, for a total transaction of $3,961,000.00. Following the completion of the sale, the chief financial officer owned 227,409 shares in the company, valued at $11,370,450. This represents a 25.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR traded down $1.02 on Friday, hitting $50.15. The stock had a trading volume of 644,236 shares, compared to its average volume of 742,348. The stock has a market cap of $3.59 billion, a P/E ratio of -14.44 and a beta of 2.17. Kymera Therapeutics, Inc. has a 1 year low of $19.44 and a 1 year high of $53.27. The firm's fifty day simple moving average is $43.75 and its two-hundred day simple moving average is $37.75.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%.The business had revenue of $11.48 million during the quarter, compared to the consensus estimate of $17.37 million. During the same period last year, the business posted ($0.58) earnings per share. The firm's quarterly revenue was down 55.1% on a year-over-year basis. Equities research analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Institutional Investors Weigh In On Kymera Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Siren L.L.C. raised its holdings in Kymera Therapeutics by 9.1% in the 1st quarter. Siren L.L.C. now owns 3,240,313 shares of the company's stock valued at $88,687,000 after buying an additional 270,580 shares during the period. Ameriprise Financial Inc. purchased a new position in shares of Kymera Therapeutics during the fourth quarter worth approximately $344,000. Rhumbline Advisers grew its position in shares of Kymera Therapeutics by 9.0% during the first quarter. Rhumbline Advisers now owns 69,928 shares of the company's stock worth $1,914,000 after acquiring an additional 5,771 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Kymera Therapeutics by 3,851.5% during the first quarter. GAMMA Investing LLC now owns 6,678 shares of the company's stock worth $183,000 after purchasing an additional 6,509 shares during the period. Finally, Millennium Management LLC lifted its holdings in shares of Kymera Therapeutics by 205.0% during the fourth quarter. Millennium Management LLC now owns 115,918 shares of the company's stock worth $4,663,000 after purchasing an additional 77,912 shares during the period.

Analysts Set New Price Targets

A number of brokerages have issued reports on KYMR. The Goldman Sachs Group raised shares of Kymera Therapeutics to a "strong-buy" rating in a report on Tuesday, July 15th. Wells Fargo & Company decreased their target price on shares of Kymera Therapeutics from $57.00 to $53.00 and set an "overweight" rating for the company in a report on Thursday, June 26th. Wall Street Zen cut shares of Kymera Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 16th. Jefferies Financial Group set a $64.00 price objective on shares of Kymera Therapeutics and gave the company a "buy" rating in a report on Wednesday, June 25th. Finally, Barclays began coverage on shares of Kymera Therapeutics in a report on Wednesday. They set an "overweight" rating and a $60.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, Kymera Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $59.95.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.